person · Reporting owner
Gallagher Carol Giltner
Disclosed activity across 11 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ANAPTYSBIO, INCANAB · Entity 4640 | Director | February 02, 2018 | February 06, 2018 |
| Annexon, Inc.ANNX · Entity 5011 | Director | July 23, 2020 | July 23, 2020 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Director | June 10, 2025 | June 13, 2025 |
| Certara, Inc.CERT · Entity 787 | Director | June 15, 2021 | June 16, 2021 |
| Metacrine, Inc.MTCR · Entity 115177 | Director | September 15, 2020 | September 15, 2020 |
| PMV Pharmaceuticals, Inc.PMVP · Entity 7062 | Director | June 04, 2026 | June 05, 2026 |
| TRex Bio, Inc.TRXB · Entity 184308 | Director | October 08, 2026 | October 09, 2026 |
| Tempest Therapeutics, Inc.MLND · Entity 7734 | Director | June 22, 2020 | June 23, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ANAPTYSBIO, INC
Report date February 02, 2018 · Filed February 06, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $104.81 · Expires 2028-02-01 | Direct | 6,000 |
Reported balance
After 2018-02-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-02-02 · Grant · Acquired 6,000 · Balance 6,000 F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests and becomes exercisable in 12 equal monthly installments beginning on March 2, 2018, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date.
Annexon, Inc.
Report date July 23, 2020 · Filed July 23, 2020
This filing explicitly reported no securities owned.
Atara Biotherapeutics, Inc.
Report date June 10, 2025 · Filed June 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,012 |
Reported balance
After 2025-06-10 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-06-10 · Grant · Acquired 7,828 · Balance 33,012 F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service.
F2: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024.
Certara, Inc.
Report date June 15, 2021 · Filed June 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,059 |
Reported balance
After 2021-06-15 transaction · row 1
1 source rowRow 1 · 2021-06-15 · Grant · Acquired 7,059 · Balance 7,059 F1: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting.
Metacrine, Inc.
Report date September 15, 2020 · Filed September 15, 2020
This filing explicitly reported no securities owned.
PMV Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 42,000 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | Direct | 0 |
Reported balance
After 2026-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-04 · Gift · Disposed 42,000 · Balance 0 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2036-06-04 | IndirectSee footnote | 42,000 |
Reported balance
After 2026-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-04 · Gift · Acquired 42,000 · Balance 42,000 F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. F2: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders.
F2: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee.
TRex Bio, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00 · Expires 2036-10-08 | Direct | 17,500 |
Reported balance
After 2026-10-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-10-08 · Grant · Acquired 17,500 · Balance 17,500 F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date.
Tempest Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2030-06-21 | Direct | 12,000 |
Reported balance
After 2020-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-22 · Grant · Acquired 12,000 · Balance 12,000 F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Frazier Lifesciences Acquisition Corp
Report date November 22, 2022 · Filed November 23, 2022
Section 16 reporting ended · disclosed 2022-11-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-11-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-11-22 · Exercise / conversion · Disposed 30,000 · Balance 0 F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022.
Mirati Therapeutics, Inc.
Report date January 23, 2024 · Filed January 24, 2024
Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,808 |
Reported balance
After 2024-01-23 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-01-23 · Disposition to issuer · Disposed 7,555 · Balance 6,808 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-01-23 · Disposition to issuer · Disposed 6,808 · Balance 0 F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $38.02 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2024-01-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-23 · Disposition to issuer · Disposed 12,784 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.
F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.
F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
F4: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting.
F5: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).
Turning Point Therapeutics, Inc.
Report date August 17, 2022 · Filed August 17, 2022
Section 16 reporting ended · disclosed 2022-08-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.39 · Expires 2030-06-14 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $65.64 · Expires 2031-06-01 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 8,500 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.99 · Expires 2029-07-23 | IndirectBy the Gallagher Revocable Trust dated May 10, 2011 | 0 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 9, 2026 01:50 UTC | TRex Bio, Inc. TRXB · Entity 184308 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0001193125-26-418292 · ownership.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2036-10-08 F1 · derivative.exercise_date: The option vests in full on October 8, 2027, subject to the reporting person's continued service through such date. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001329959-26-000002 · form4-06052026_080616.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. F2 · ownership.nature: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001329959-26-000002 · form4-06052026_080616.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 04, 2026 Filed Jun 5, 2026 20:25 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 42,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001329959-26-000002 · form4-06052026_080616.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,000 Underlying: Common Stock · 42,000 shares Expires 2036-06-04 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 4, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 00:39 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 7,828 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-002142 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,012 F1 · shares: These restricted stock units shall vest on the earlier of June 10, 2026 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2 · balance_after: This amount reflects the 1:25 reverse stock split effected by the Issuer on June 20, 2024. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:23 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016262 · form4-06092025_080644.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. F2 · ownership.nature: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:23 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016262 · form4-06092025_080644.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:23 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 33,500 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001415889-25-016262 · form4-06092025_080644.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 5, 2026 or (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016208 · form4-06102024_080606.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. F2 · ownership.nature: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. Read SEC document |
| June 07, 2024 Filed Jun 10, 2024 20:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016208 · form4-06102024_080606.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. Read SEC document |
| June 06, 2024 Filed Jun 10, 2024 20:21 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 67,500 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001415889-24-016208 · form4-06102024_080606.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2034-06-05 F1 · derivative.exercise_date: The option vests as follows: 22,500 shares vest on the earlier of (i) June 6, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders and the remaining 45,000 shares vest in 36 equal monthly installments beginning on July 6, 2024. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 22:12 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001057 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 629,608 F1 · shares: These restricted stock units shall vest on the date of the Issuer's annual meeting of stockholders for the calendar year 2025, subject to the Reporting Person's continuous service. F2 · balance_after: This amount includes an additional 20,190 shares that were previously inadvertently omitted from the Reporting Person's aggregate beneficial ownership. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,784 | Not disclosed Strike: $38.02 | Not disclosed |
DisclosureSEC source: 0001140361-24-003527 · form4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,784 shares Expires 2033-06-21 F5 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 6,808 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003527 · form4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the Merger Agreement and the Company Equity Plans (as such term is defined in the Merger Agreement), at the Effective Time, each of these RSUs that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash award of BMS in an amount equal to the product of the number of restricted stock units subject to such RSU immediately prior to the Effective Time and the last trading price of a share of Company Common Stock before the Effective Time (the "Converted Cash Award"). Following the Effective Time, the Converted Cash Award will be subject to the same terms and conditions applicable to such Issuer RSUs, including with respect to vesting. Read SEC document |
| January 23, 2024 Filed Jan 24, 2024 01:37 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | Disposition to issuerCommon Stock | 7,555 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-24-003527 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,808 F1 · security: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · security: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document |
| December 29, 2023 Filed Jan 3, 2024 23:27 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 6,808 | $58.75 | $399,970.00 |
DisclosureSEC source: 0001628280-24-000312 · wk-form4_1704324430.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,363 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the anniversary of the grant date. Read SEC document |
| November 14, 2023 Filed Nov 15, 2023 22:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 90,980 | $0.31 | $28,185.60 |
DisclosureSEC source: 0000905148-23-001457 · form4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,418 F2 · price: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.2862 to $0.3229. Read SEC document |
| November 13, 2023 Filed Nov 15, 2023 22:07 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | PurchaseCommon Stock | 179,020 | $0.22 | $40,028.87 |
DisclosureSEC source: 0000905148-23-001457 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,438 F1 · price: Represents the weighted average purchase price. The shares were purchased in multiple transactions at prices ranging from $0.205 to $0.251. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantEmployee Stock Option (Right to Buy) · Derivative | 12,784 | $0.00 Strike: $38.02 | $0.00 |
DisclosureSEC source: 0001628280-23-023351 · wk-form4_1687555072.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,784 Underlying: Common Stock · 12,784 shares Expires 2023-06-22 F2 · derivative.exercise_date: The shares subject to the Option shall vest and become exercisable in 36 equal monthly installments following the date of grant. Read SEC document |
| June 22, 2023 Filed Jun 23, 2023 21:18 UTC | Mirati Therapeutics, Inc. MRTX · Entity 94908 | GrantCommon Stock | 7,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-023351 · wk-form4_1687555072.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,555 F1 · kind: This represents a Restricted Stock Unit grant with a vesting period of 3 years that vests 33% annually from grant date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:19 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036383 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. F2 · ownership.nature: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:19 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036383 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 21:19 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 21,500 | $0.00 Strike: $5.59 | $0.00 |
DisclosureSEC source: 0001209191-23-036383 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,500 Underlying: Common Stock · 21,500 shares Expires 2033-06-07 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 8, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 79,500 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001140361-23-028153 · form4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,500 Underlying: Common Stock · 79,500 shares Expires 2033-05-30 F2 · derivative.exercise_date: The option shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 57,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-028153 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 189,418 F1 · shares: These restricted stock units shall vest on the earlier of May 31, 2024 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 21:23 UTC | Frazier Lifesciences Acquisition Corp FLAC · Entity 122080 | Exercise / conversionClass B Ordinary Shares · Derivative | 30,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-036923 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Ordinary Shares · 30,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · price: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.exercise_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. F1 · derivative.expiration_date: Pursuant to the terms outlined in the Business Combination Agreement, dated July 25, 2022, by and among NewAmsterdam Pharma Holding B.V., Frazier Lifesciences Acquisition Corporation, NewAmsterdam Pharma Investment Corporation, and NewAmsterdam Pharma Company B.V., these shares were automatically converted into Class A ordinary shares of NewAmsterdam Pharma Company N.V. (Nasdaq symbol "NAMS"). The Business Combination closed on November 22, 2022. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 21:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-22-056102 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2032-11-03 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal, monthly installments beginning on December 4, 2022. F2 · ownership.nature: The securities are held of record by The Gallagher Revocable Trust dated May 10, 2011 for which the reporting person serves as a trustee. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 21:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GiftStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-22-056102 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2032-11-03 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal, monthly installments beginning on December 4, 2022. Read SEC document |
| November 04, 2022 Filed Nov 8, 2022 21:22 UTC | PMV Pharmaceuticals, Inc. PMVP · Entity 7062 | GrantStock Option (right to buy) · Derivative | 39,000 | $0.00 Strike: $11.28 | $0.00 |
DisclosureSEC source: 0001209191-22-056102 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,000 Underlying: Common Stock · 39,000 shares Expires 2032-11-03 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal, monthly installments beginning on December 4, 2022. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:38 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 30,000 | Not disclosed Strike: $39.99 | Not disclosed |
DisclosureSEC source: 0001209191-22-046284 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Gallagher Revocable Trust dated May 10, 2011 Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-07-23 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:38 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 8,500 | Not disclosed Strike: $65.64 | Not disclosed |
DisclosureSEC source: 0001209191-22-046284 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2031-06-01 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| August 17, 2022 Filed Aug 17, 2022 20:38 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | Disposition to issuerStock Option (right to buy) · Derivative | 8,500 | Not disclosed Strike: $65.39 | Not disclosed |
DisclosureSEC source: 0001209191-22-046284 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,500 shares Expires 2030-06-14 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 2, 2022, by and among Turning Point Therapeutics, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and Rhumba Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on August 17, 2022, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option multiplied by (ii) the excess of (x) $76.00 per Share over (y) the exercise price payable per Share under such option, net of any withholding taxes required to be deducted and withheld by applicable law. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 31,500 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001140361-22-024166 · form4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2032-06-22 F3 · derivative.exercise_date: The option shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 20:48 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-22-024166 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,418 F1 · shares: These restricted stock units shall vest on the earlier of June 23, 2023 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. F2 · balance_after: The amount of securities beneficially owned by the reporting person shown here corrects an inadvertent understatement of 100 shares in a prior Form 4. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 12:48 UTC | Certara, Inc. CERT · Entity 787 | GrantCommon Stock | 7,059 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-003028 · form4-06162021_050625.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,059 F1 · kind: Represents 7,059 restricted stock units ("RSU") granted under the Certara Inc. 2020 Incentive Plan that will entitle the reporting person to receive one share of the Issuer's Common Stock per RSU. The RSUs will vest on the earlier of the one-year anniversary of the date of grant or the date of the Company's next annual stockholder meeting. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $13.80 | $0.00 |
DisclosureSEC source: 0001140361-21-020437 · form4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F2 · derivative.exercise_date: The option shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2021 Filed Jun 9, 2021 23:09 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-21-020437 · form4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,818 F1 · shares: These restricted stock units shall vest on the earlier of June 8, 2022 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 21:39 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $65.64 | $0.00 |
DisclosureSEC source: 0001209191-21-038333 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2031-06-01 F1 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 11:07 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.40 | $0.00 |
DisclosureSEC source: 0001544227-20-000033 · wf-form4_159291041152553.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-21 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on the earlier of (1) June 22, 2021 and (2) the date of the first Annual Meeting following the grant date, subject to the Reporting Person continuing to provide service to the Issuer through such date. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 24,500 | $0.00 Strike: $10.54 | $0.00 |
DisclosureSEC source: 0001209191-20-037367 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,500 Underlying: Common Stock · 24,500 shares Expires 2030-06-15 F2 · derivative.exercise_date: The option shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 16, 2020 Filed Jun 17, 2020 21:46 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-037367 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,818 F1 · shares: These restricted stock units shall vest on the earlier of June 16, 2021 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 22:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 8,500 | $0.00 Strike: $65.39 | $0.00 |
DisclosureSEC source: 0001209191-20-037410 · doc4.xml · derivative · entry 3 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2030-06-14 F3 · derivative.exercise_date: The shares vest on the one-year anniversary of the date of grant. Read SEC document |
| August 27, 2019 Filed Jun 17, 2020 22:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GiftStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $39.99 | $0.00 |
DisclosureSEC source: 0001209191-20-037410 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Gallagher Revocable Trust dated May 10, 2011 Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-07-23 F2 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant. Read SEC document |
| August 27, 2019 Filed Jun 17, 2020 22:47 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GiftStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $39.99 | $0.00 |
DisclosureSEC source: 0001209191-20-037410 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2029-07-23 F1 · kind: The Reporting Person contributed this option, for no consideration, to a trust for the benefit of the Reporting Person. The Reporting Person remains the beneficial owner of the option. F2 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant. Read SEC document |
| July 24, 2019 Filed Jul 25, 2019 20:12 UTC | Turning Point Therapeutics, Inc. TPTX · Entity 124461 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $39.99 | $0.00 |
DisclosureSEC source: 0001209191-19-043220 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-07-23 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantNon-Qualified Stock Option (Right to Buy) · Derivative | 13,000 | $0.00 Strike: $20.25 | $0.00 |
DisclosureSEC source: 0001209191-19-039767 · doc4.xml · derivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Stock · 13,000 shares Expires 2029-06-26 F2 · derivative.exercise_date: The option shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 27, 2019 Filed Jul 1, 2019 21:00 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-039767 · doc4.xml · nonDerivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,818 F1 · shares: These restricted stock units shall vest on the earlier of June 27, 2020 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:35 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $11.59 | $0.00 |
DisclosureSEC source: 0001209191-19-038479 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-19 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on June 20, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:46 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $8.80 | $0.00 |
DisclosureSEC source: 0001209191-19-004235 · doc4.xml · derivative · entry 1 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2029-01-14 F1 · derivative.exercise_date: One hundred percent (100%) of the shares subject to this option will vest on January 15, 2020, subject to the Reporting Person continuing to provide service through such date. Read SEC document |
| December 07, 2018 Filed Dec 12, 2018 00:38 UTC | Tempest Therapeutics, Inc. MLND · Entity 7734 | GrantCommon Stock | 23,684 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-062111 · doc4.xml · nonDerivative · entry 2 Gallagher Carol Giltner · CIK 0001329959 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By: Gallagher Revocable Trust Disclosed balance after: 23,684 F2 · price: Received in exchange for 318,335 shares of Millendo Therapeutics, Inc. common stock in connection with merger of Millendo Therapeutics, Inc. into the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.